Aurobindo Pharma CDMO

Aurobindo Pharma Limited is one of the largest generic pharmaceutical companies globally, with a strong commitment to making medicines affordable and accessible. The company operates 29 manufacturing facilities across the globe with manufacturing capacities of 50+ billion formulation units and 19,000+ MT of APIs, supported by advanced vertical integration. Aurobindo maintains a presence across 150+ global markets including the US, Europe, and Growth Markets, and is ranked among the top 10 generic companies across eight countries in Europe. The company has filed 830 US ANDAs with 600+ approvals. Aurobindo offers a strong and sustainable pipeline of high-value biosimilar programs with primary focus on Oncology and Immunology therapeutic segments. The organization is committed to innovation and research with significant R&D investments.